We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

A. Menarini Diagnostics S.r.l.

A. Menarini Diagnostics S.r.l. is fully committed to developing high tech diagnostics instruments and reagents to imp... read more Featured Products: More products

Download Mobile App




Events

02 Jun 2025 - 04 Jun 2025
11 Jun 2025 - 13 Jun 2025

Early Blood Test Predicts Survival in Patients with Metastatic Prostate Cancer

By LabMedica International staff writers
Posted on 08 Oct 2024

Before prostate cancer spreads, it can be effectively treated with surgery or radiation. More...

However, once the cancer metastasizes and becomes incurable, systemic treatments are used to extend survival as much as possible. Biomarkers that predict patient responses to these treatments could enable better personalization of care, but such markers are rare. Now, a new blood test, conducted when metastatic prostate cancer is first diagnosed, can predict which patients are most likely to respond to treatment and have the longest survival rates. This test can help clinicians determine which patients should receive standard treatments and who might benefit from more aggressive and experimental drug trials.

A recent study demonstrated that measuring circulating tumor cells (CTCs), which are rare cancer cells shed from tumors into the bloodstream, is a reliable method to predict future treatment responses and survival outcomes. Although CTCs have been studied in later stages of prostate cancer, this was the first time researchers at the USC Norris Comprehensive Cancer Center (Los Angeles, CA, USA) assessed whether CTC counts at the initial diagnosis of metastatic prostate cancer can predict long-term survival or treatment progression. The researchers used Menarini's (Bologna, Italy) CellSearch, an FDA-cleared liquid biopsy technology, to detect and measure CTCs in blood samples. CellSearch utilizes immunomagnetic beads, with antibodies attached to magnetic particles, to bind to CTCs in the blood and isolate them for detection and counting by specialized equipment.

The research, published in JAMA Network Open, revealed that patients with five or more CTCs in their blood samples had the poorest outcomes. Compared to patients with zero CTCs, they were 3.22 times more likely to die during the study and 2.46 times more likely to experience cancer progression. They were also significantly less likely—0.26 times—to achieve a complete prostate-specific antigen (PSA) response, indicating a poor treatment response. Men with five or more CTCs had a median survival of 27.9 months after the blood test, compared to 56.2 months for those with one to four CTCs, and at least 78 months for men with zero CTCs. The findings indicated that higher CTC counts were associated with shorter survival, faster disease progression, and a weaker response to standard treatments.

This study highlights that measuring CTC counts at the onset of therapy can predict long-term survival, even for men who undergo multiple treatments over several years for metastatic prostate cancer. The test could help identify candidates early for trials of newer, potentially more aggressive therapies. The researchers believe that the widely available CellSearch blood test could quickly flag patients who are unlikely to respond to standard treatment, potentially guiding them toward more intensive therapies, including clinical trials of new drugs with higher risks but possible survival benefits for high-risk patients. The team is now working on a new blood test that not only counts CTCs but also analyzes their molecular composition, tumor DNA circulating in the blood, and other factors. Their goal is to develop even more predictive biomarkers to better match patients with tailored treatment options.

“You couldn’t tell these men apart when they walked through the door,” said Amir Goldkorn, MD, lead author of the study and associate director of translational sciences at the USC Norris Comprehensive Cancer Center. “All of their other variables and prognostic factors were seemingly the same, and yet they had very, very different outcomes over time. We want to enrich these clinical trials with men who need all that extra help—who really would benefit from three drugs versus just two, or from being on a new chemotherapy drug, even though it may have more side effects.”

Related Links:
USC Norris Comprehensive Cancer Center 
Menarini Silicon Biosystems


Gold Member
Troponin T QC
Troponin T Quality Control
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
New
UHF RFID Tag & Inlay
AD-327 U9 ETSI Pure 95
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: The new tool is designed for accurate detection of structural variations in clinical samples (Photo courtesy of Karen Arnott/EMBL-EBI and Isabel Romero Calvo/EMBL)

ML Algorithm Accurately Identifies Cancer-Specific Structural in Long-Read DNA Sequencing Data

Long-read sequencing technologies are designed to analyze long, continuous stretches of DNA, offering significant potential to enhance researchers' abilities to detect complex genetic changes in cancer genomes.... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.